
May 7 @ 5:30 pm – 8:30 pm PDT
Anti-resorptive medications provide life-saving and life-enhancing benefits to patients with certain cancers, osteoporosis, and other bone metabolism conditions. Inadequate treatment of dental disease in this patient population may occur due to patient and provider fears of Medication Related Osteonecrosis of the Jaws (MRONJ). This course will review key anti-resorptive pharmacology and physiology, strategies to determine and mitigate risks of developing MRONJ, referral guidelines, general principles of MRONJ management, and abundant patient cases to help participants confidently engage in shared decision-making with their patients.
CDA publishes events based on submissions from event organizers and cannot guarantee the accuracy of the information provided.